Comparative effects of vonoprazan-based and esomeprazole-based dual therapy on Helicobacter pylori eradication and short-term gut microbiota changes

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Objective This study aimed to compare the Helicobacter pylori (H. pylori) eradication efficacy, safety, patient compliance, and short-term effects on the gut microbiota of vonoprazan-based potassium-competitive acid blocker (P-CAB) dual therapy and esomeprazole-based proton pump inhibitor (PPI) dual therapy. Methods A total of 110 H. pylori-positive patients were enrolled and non-randomly assigned to the P-CAB group ( n = 50, vonoprazan 20 mg bid + amoxicillin 750 mg qid) or the PPI group ( n = 60, esomeprazole 20 mg qid + amoxicillin 750 mg qid). Twenty-two H. pylori-negative individuals served as healthy controls (HC). Eradication was assessed by the ¹³C-urea breath test four weeks after treatment. Fecal samples were collected at baseline (week 0), after eradication (week 2), and at confirmation (week 6) for 16 S rRNA gene sequencing to analyze gut microbiota diversity, composition, and functional changes. Results The P-CAB group showed a higher eradication rate than the PPI group across all analysis sets, reaching statistical significance only in the per-protocol analysis (97.73% vs. 84.20%, P = 0.04). Adverse reactions and patient compliance did not differ between the two groups ( P > 0.05). Both regimens altered the diversity, composition, and functional pathways of the gut microbiota, with gradual recovery over time. Initial declines in microbial diversity were more pronounced in the P-CAB group, while functional pathway recovery tended to be faster. Both groups showed an increase in potential pathogenic bacteria and a decrease in short-chain fatty acid-producing bacteria after treatment. Conclusions VA dual therapy achieved a higher H. pylori eradication rate than EA dual therapy in all analysis sets, but statistical significance was reached only in the per-protocol analysis. Safety and patient compliance were comparable between the two regimens. Both treatments transiently disrupted the diversity, composition, and function of the gut microbiota, with gradual recovery over time.